Supplementary Table S5: Treatment-related adverse events

n (%)	Escalation monotherapy (*N*=21)		Escalation combination (*N*=15)		Expansion combination (*N*=41)	
	All grades	**Grade ≥3**	**All grades**	**Grade ≥3**	**All grades**	**Grade ≥3**
Infections and infestations						
Body tinea	1 (4.8)	0	0	0	0	0
Tinea pedis	1 (4.8)	0	0	0	0	0
Urinary tract infection	1 (4.8)	0	0	0	00	
Clostridium difficile colitis	0	0	0	0	1 (2.4)	0
Vulvovaginal candidiasis	0	0	0	0	1 (2.4)	0
Neoplasms benign, malignant and unspecified (Incl cysts and polyps)						
Acanthoma	1 (4.8)	0	0	0	0	0
Tumor pain	1 (4.8)	0	0	0	1 (2.4)	0
Tumour haemorrhage	0	0	0	0	1 (2.4)	0
Blood and lymphatic system disorders						
Anaemia	1 (4.8)	0	0	0	1 (2.4)	0
Thrombocytosis	1 (4.8)	0	0	0	0	0
Endocrine disorders						
Hypothyroidism	1 (4.8)	0	0	0	0	0
Adrenal insufficiency	0	0	1 (6.7)	0	1 (2.4)	0
Hypophysitis	0	0	0	0	1 (2.4)	0
Hyperthyroidism	0	0	1 (6.7)	0	0	0
Psychiatric disorders						
Anxiety	1 (4.8)	0	0	0	0	0
Insomnia	1 (4.8)	0	0	0	0	0
Libido decreased	0	0	0	0	1 (2.4)	0
Eye disorders						
Xerophthalmia	1 (4.8)	0	0	0	0	0
Dry eye	0	0	0	0	0	0
Keratitis	0	0	3 (20.0)	0	0	0
Foreign body sensation in eyes	0	0	2 (13.3)	0	1 (2.4)	0
Lacrimation increased	0	0	0	0	1 (2.4)	0
Photopsia	0	0	0	0	1 (2.4)	0
Vision blurred	0	0	0	0	1 (2.4)	0
Ear and labyrinth disorders						
Vertigo	1 (4.8)	0	0	0	0	0

Cardiac disorders						
Heart valve incompetence	1 (4.8)	0	0	0	0	0
Hypertensive heart disease	1 (4.8)	0	0	0	0	0
Vascular disorders						
Hypertension	1 (4.8)	0	0	0	0	0
Hypotension	0	0	2 (13.3)	0	1 (2.4)	0
Gastrointestinal disorders						
Vomiting	2 (9.5)	0	2 (13.3)	0	4 (9.8)	0
Dry mouth	1 (4.8)	0	2 (13.3)	0	1 (2.4)	0
Nausea	0	0	3 (20.0)	0	3 (7.3)	0
Diarrhoea	0	0	2 (13.3)	0	5 (12.2)	1 (2.4)
Constipation	0	0	2 (13.3)	0	1 (2.4)	0
Noninfective gingivitis	0	0	1 (6.7)	0	0	0
Abdominal pain	0	0	0	0	1 (2.4)	0
Abdominal pain lower	0	0	0	0	1 (2.4)	0
Skin and subcutaneous tissue disorders						
Hyperhidrosis	1 (4.8)	0	0	0	0	0
Rash	1 (4.8)	0	0	0	3 (7.3)	0
Dry skin	0	0	3 (20.0)	0	0	0
Dermatitis acneiform	0	0	1 (6.7)	0	0	0
Pruritus	0	0	1 (6.7)	0	6 (14.6)	0
Rash maculo-papular	0	0	1 (6.7)	0	0	0
Vitiligo	0	0	1 (6.7)	0	2 (4.9)	0
Alopecia	0	0	0	0	1 (2.4)	0
Dry skin	0	0	0	0	1 (2.4)	0
Eczema	0	0	0	0	1 (2.4)	0
Erythema	0	0	0	0	1 (2.4)	0
Intertrigo	0	0	0	0	1 (2.4)	0
Urticaria	0	0	0	0	1 (2.4)	0
Musculoskeletal and connective tissue disorders						
Arthralgia	1 (4.8)	0	1 (6.7)	0	1 (2.4)	0
Musculoskeletal pain	1 (4.8)	0	0	0	0	0
Myalgia	1 (4.8)	0	1 (6.7)	0	1 (2.4)	0
Pain in extremity	1 (4.8)	0	0	0	0	0
Groin pain	0	0	0	0	1 (2.4)	0
Muscle spasms	0	0	0	0	1 (2.4)	0
Muscular weakness	0	0	0	0	1 (2.4)	1 (2.4)
General disorders and administration site conditions						

Fatigue	2 (9.5)	0	7 (46.7)	0	7 (17.1)	1 (2.4)
Chills	2 (9.5)	0	2 (13.3)	0	1 (2.4)	0
Injection site erythema	1 (4.8)	0	0	0	3 (7.3)	0
Injection site haematoma	1 (4.8)	0	0	0	0	0
Injection site haemorrhage	1 (4.8)	0	0	0	0	0
Injection site reaction	1 (4.8)	0	0	0	2 (4.9)	0
Injection site swelling	1 (4.8)	0	0	0	1 (2.4)	0
Pyrexia	1 (4.8)	0	3 (20.0)	0	2 (4.9)	0
Malaise	0	0	3 (20.0)	0	0	0
Asthenia	0	0	1 (6.7)	0	5 (12.2)	0
Injection site pain	0	0	1 (6.7)	0	11 (26.8)	1 (2.4)
Injection site ulcer	0	0	1 (6.7)	0	0	0
General physical health deterioration	0	0	0	0	1 (2.4)	1 (2.4)
Inflammation	0	0	0	0	1 (2.4)	0
Injection site inflammation	0	0	0	0	1 (2.4)	0
Injection site oedema	0	0	0	0	1 (2.4)	0
Injection site swelling	0	0	0	0	1 (2.4)	0
Oedema peripheral	0	0	0	0	1 (2.4)	0
Investigations						
Blood alkaline phosphatase increased	1 (4.8)	0	0	0	0	0
Gamma-glutamyl transferase increased	1 (4.8)	0	0	0	0	0
Glomerular filtration rate decreased	1 (4.8)	0	0	0	0	0
Amylase increased	0	0	0	0	2 (4.9)	0
Aspartate aminotransferase increased	0	0	0	0	2 (4.9)	0
Blood alkaline phosphatase increased	0	0	0	0	2 (4.9)	0
C-reactive protein increased	0	0	0	0	2 (4.9)	0
Alanine aminotransferase increased	0	0	0	0	1 (2.4)	0
Lipase increased	0	0	0	0	1 (2.4)	0
Monocyte count increased	0	0	0	0	1 (2.4)	0
Troponin increased	0	0	0	0	1 (2.4)	1 (2.4)
Weight decreased	0	0	0	0	1 (2.4)	0
Metabolism and nutrition disorders						
Decreased appetite	0	0	2 (13.3)	0	4 (9.8)	0
Dehydration	0	0	0	0	1 (2.4)	0

Hyperlipasaemia	0	0	0	0	1 (2.4)	1 (2.4)
Hypokalaemia	0	0	0	0	1 (2.4)	00
Nervous system disorders						
Dizziness	0	0	3 (20.0)	1 (6.7)	0	0
Headache	0	0	1 (6.7)	0	0	0
Paraesthesia	0	0	1 (6.7)	0	0	0
Syncope	0	0	1 (6.7)	0	0	0
Neuropathy peripheral	0	0	1 (6.7)	1 (6.7)	0	0
Injury, poisoning and procedural complications						
Infusion related reaction	0	0	1 (6.7)	0	0	0
Post procedural fever	0	0	1 (6.7)	0	0	0
Procedural dizziness	0	0	0	0	1 (2.4)	0
Immune system disorders						
Cytokine release syndrome	0	0	0	0	2 (4.9)	0
Respiratory, thoracic and mediastinal disorders						
Pulmonary embolism	0	0	0	0	1 (2.4)	0
Renal and urinary disorders						
Proteinuria	0	0	0		1 (2.4)	0

n, number of patients.